DATA: 20/12/2019
Il X Congresso Nazionale è stato un successo!

Oltre 700 clinici esperti nelle IBD si sono confrontati su diagnosi, terapia e modelli gestionali.

Live the present, envision the future


28 November
H. Sokol Microbiome and immune system interaction in IBD
M.V. Lenti PREVALENCE OF ANAEMIA IN INFLAMMATORY BOWEL DISEASE: PRELIMINARY RESULTS OF THE OBSERVATIONAL ITALIAN MULTICENTRE IG IBD STUDY RIDART 1
C. Mengoli HUMAN CYTOMEGALOVIRUS AND EPSTEIN BARR VIRUS SPECIFIC T CELL IMMUNITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
C. Marinelli Serum PCSK9 as novel biomarker for inflammation and cardiovascular risk in ulcerative colitis
N. Imperatore PREVALENCE OF INFECTIONS IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE TREATED WITH ANTI TNF ALPHA AGENTS : A SINGLE CENTER EXPERIENCE
M.G. Demarzo Therapeutic Drug Monitoring in Crohn’s Disease Patients, a Comparison Between Homogeneous Mobility Shift Assay and Point of Care Method
A. Rispo Medical Therapy in Refractory IBD: When enough is enough
S. Renna “MEDICAL THERAPY IN REFRACTORY IBD: WHEN ENOUGH IS ENOUGH?” Ulcerative colitis
F. Rizzello Refractory Pouchitis

29 November
D. Guagnozzi "Microscopic colitis: current management"
M.V. Lenti ARE WE CHOOSING WISELY IN INFLAMMATORY BOWEL DISEASE CARE? THE IG IBD CHOOSING WISELY CAMPAIGN
P. Alvisi Ten years data from the SIGENP Inflammatory Bowel Disease registry Alvisi
A. Armuzzi Association Between Histologic Indices and Ulcerative Colitis Activity Measures Among Patients in the HICKORY Etrolizumab ) Open Label Induction Cohort
C. Marinelli Prevalence and risk factors for sleep disturbance in Inflammatory Bowel Disease A cross sectional study
M.V. Lenti STIGMATISATION AND RESILIENCE IN INFLAMMATORY BOWEL DISEASE. RESULTS FROM AN ITALIAN, SINGLE CENTRE, LONGITUDINAL STUDY
I. Marafini HIGH FREQUENCY OF UNDIAGNOSED MENTAL ILLNESS IN INFLAMMATORY BOWEL DISEASES
K. Gerasimidis Diet and food additives in IBD Foe or Friend?
F. Castiglione FUTURE BENCHMARKS IN IBD. Disability in IBD
G. Fiorino STANDARDS OF CARE IN IBD
A. Kohn Acute Severe Ulcerative Colitis
G. Mocci CLINICAL AND EPIDEMIOLOGICAL FEATURES OF ULCERATIVE C OLITIS PATIENTS IN SARDINIA, ITALY: RESULTS FROM A MULTICENTER STUDY
G. Mocci QUALITY OF LIFE AND PERCEPTION OF CARE FOR ULCERATIVE COLITIS PATIENTS IN SARDINIA: RESULTS OF A MULTICENTER OBSERVATIONAL STUDY
A. Vitello RESULTS OF A RETROSPECTIVE IGIBD STUDY ON ADALIMUMAB USE IN REAL PRACTICE IN ITALY: THE REAL LIFE CLINICAL EFFECTIVENESS OF ADALIMUMAB IN ULCERATIVE COLITIS (REALADA UC) STUDY
G. Privitera EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR IN A LARGE COHORT OF IBD PATIENTS
F.S. Macaluso A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB AND ADALIMUMAB IN CROHN’S DISEASE REAL LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN IBD)
M.R. Giuffrè Fecal Microbiota Transplantation Controls Murine Chronic Intestinal Inflammation by Modulating Immune Cell Functions and Gut Microbiota Composition
D. Pugliese Common errors in the management of IBD

30 November
G. Luglio SuPREMe-CD Study : Surgical Prevention of anastomotic Recurrence by Excluding Mesentery in Crohn's Disease. Preliminary results and trial protocol. Trial update.
G.M. Sampietro FEASIBILITY AND SAFETY OF STRICTUREPLASTIES PERFORMED BY LAPAROSCOPIC APPROACH FOR COMPLICATED CROHN’S DISEASE. A PROSPECTIVE, OBSERVATIONAL, COHORT STUDY
D.G. Ribaldone RISK FACTORS AND PROGNOSTIC SIGNIFICANCE OF JOINT MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS: APPLICATION OF THE STRII QUESTIONNAIRE
A. Cassinotti DIAGNOSTIC ACCURACY OF VIRTUAL CHROMOENDOSCOPY WITH NARROW BAND IMAGING (NBI) FOR THE CLASSIFICATION OF POLYPOID AND NON-POLYPOID LESIONS IN ULCERATIVE COLITIS: A PROSPECTIVE STUDY USING DIFFERENT ENDOSCOPIC CLASSIFICATIONS
G. Dragoni THE Y-ECCO/CLINCOM 2019 SURVEY ON POSTOPERATIVE CROHN’S DISEASE RECURRENCE SUGGESTS OVERTREATMENT WITH PROPHYLACTIC BIOLOGICAL THERAPY
G. Zerboni A NEW QUESTIONNAIRE TO INVESTIGATE PATIENTS’ KNOWLEDGE OF RELEVANT ASPECTS OF INFLAMMATORY BOWEL DISEASE CLINICAL COURSE AND OUTCOMES: PRELIMINARY RESULTS
F. Caprioli Future combinations in inflammatory bowel diseases
C.F. Perno Combination in HIV
L. Mazzarella Combinations in oncohematology

Percorso Terapeutico A

28 November
P. Gionchetti Key learnings from recent H2H trials and indirect comparison
A. Orlando WHAT DO THE NEW REAL WORLD COMPARATIVE EFFECTIVENESS STUDIES TELL US ?
G. Poggioli How an advanced therapy can improve the care of CD patients with complex perianal fistula?

29 November
 G. Bodini Anti-TNF alpha in IBD: from robust evidence to new horizons
 M. Daperno Drug pipeline in IBD: extracellular and intracellular cytokine-blocking

30 November
 S. Leone UNDERSTANDING PATIENTS’ EXPERIENCES AND RESPONSES TO THERAPY
 F. Costa Adalimumab biosimilar: real life Evidence from Tuscany region

Percorso Terapeutico B

28 November
M. Principi UNMET MEDICAL NEEDS IN THE ERA OF NEW BIOLOGICS
F. Caprioli Role of IL-12/23 blockade in ulcerative colitis
D. Pugliese Real-life experience with Ustekinumab in Crohn’s disease

29 November
C. Taxonera Samsò Effective early control in UC: challenges in real life
G. Fiorino Five years with infliximab CT P13: the IG IBD position update
M.L. Scribano Controlled evidences: from Nor-Switch to study 3.4